ACADIA to Host Conference Call and Webcast on Friday, May 4, 2018, at8:30 a.m. Eastern Time
SAN DIEGO, Calif.—(BUSINESS WIRE)—May 1, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its financial results for the firstquarter ended March 31, 2018 on Friday, May 4, 2018, before the U.S.financial markets open. ACADIA's management will host a conference calland webcast on Friday, May 4, 2018, at 8:30 a.m. Eastern Time to discussACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 forparticipants in the United States or Canada and 830-865-2550 forinternational callers (reference passcode 3685527). A telephone replayof the conference call may be accessed through May 18, 2018 by dialing855-859-2056 for callers in the United States or Canada and 404-537-3406for international callers (reference passcode 3685527). The conferencecall also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until May 18,2018.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines that address unmet medicalneeds in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, and the timing of future eventsor announcements. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization. For a discussion of these and otherfactors, please refer to ACADIA’s annual report on Form 10-K for theyear ended December 31, 2017 as well as ACADIA’s subsequent filings withthe Securities and Exchange Commission. You are cautioned not to placeundue reliance on these forward-looking statements, which speak only asof the date hereof. This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, (858)558-2871
Investor Relations
ir@acadia-pharm.com